Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Rhythm Pharmaceuticals Inc. BMV:RYTM
Today's live share price, quote history, chart & news
|Year to date change||N.A|
About Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals, Inc.
David P. Meeker
222 Berkeley Street, Boston, MA, 02116
|Entity name||Report date||Shares held|
Aggregated insiders summary data for the last 6 months.
|Full name||Reported title||Total bought||Total sold||Net transacted|
|Full name||Reported title||Effective date||Amount of shares||Price per share||Total cost|
Rhythm Pharmaceuticals Inc. dividends
|Ex date||Payment date||Record date||Declared date||Amount||Description||Frequency|